September 7, 2022 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee



Published
The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic lateral sclerosis (ALS).
Category
Health
Be the first to comment